CN101415685B - 激酶抑制剂及其使用方法 - Google Patents

激酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN101415685B
CN101415685B CN2007800120196A CN200780012019A CN101415685B CN 101415685 B CN101415685 B CN 101415685B CN 2007800120196 A CN2007800120196 A CN 2007800120196A CN 200780012019 A CN200780012019 A CN 200780012019A CN 101415685 B CN101415685 B CN 101415685B
Authority
CN
China
Prior art keywords
compound
disease
preparation
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800120196A
Other languages
English (en)
Chinese (zh)
Other versions
CN101415685A (zh
Inventor
R·格罗尼贝格
L·E·伯吉斯
D·哈维
E·莱尔德
M·芒森
J·里齐
M·罗德里古兹
C·T·厄利
D·沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN101415685A publication Critical patent/CN101415685A/zh
Application granted granted Critical
Publication of CN101415685B publication Critical patent/CN101415685B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2007800120196A 2006-01-31 2007-01-26 激酶抑制剂及其使用方法 Active CN101415685B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76371206P 2006-01-31 2006-01-31
US60/763,712 2006-01-31
PCT/US2007/002272 WO2007089646A1 (en) 2006-01-31 2007-01-26 Kinase inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
CN101415685A CN101415685A (zh) 2009-04-22
CN101415685B true CN101415685B (zh) 2011-08-24

Family

ID=38037453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800120196A Active CN101415685B (zh) 2006-01-31 2007-01-26 激酶抑制剂及其使用方法

Country Status (26)

Country Link
US (2) US8044083B2 (https=)
EP (1) EP1981851B1 (https=)
JP (1) JP5131990B2 (https=)
KR (1) KR101357465B1 (https=)
CN (1) CN101415685B (https=)
AT (1) ATE542800T1 (https=)
AU (1) AU2007210073B2 (https=)
BR (1) BRPI0707401B8 (https=)
CA (1) CA2635813C (https=)
CY (1) CY1112770T1 (https=)
DK (1) DK1981851T3 (https=)
ES (1) ES2379656T3 (https=)
HR (1) HRP20120256T1 (https=)
IL (3) IL192949A (https=)
MY (1) MY151835A (https=)
NZ (1) NZ570846A (https=)
PL (1) PL1981851T3 (https=)
PT (1) PT1981851E (https=)
RS (1) RS52298B (https=)
RU (1) RU2442777C2 (https=)
SG (1) SG175599A1 (https=)
SI (1) SI1981851T1 (https=)
TW (1) TWI388557B (https=)
UA (1) UA94733C2 (https=)
WO (1) WO2007089646A1 (https=)
ZA (1) ZA200806507B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
RS52298B (sr) 2006-01-31 2012-12-31 Array Biopharma Inc. Inhibitori kinaze i postupak njihove upotrebe
WO2009015000A1 (en) * 2007-07-25 2009-01-29 Array Biopharma Inc. Pyrazole urea derivatives used as kinase inhibitors
EP2196461A1 (de) 2008-12-15 2010-06-16 Bayer CropScience AG 4-Amino-1,2,3-benzoxathiazin-Derivate als Pestizide
CA2835835C (en) 2011-05-13 2019-04-02 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
SI2819998T1 (sl) * 2012-03-01 2022-07-29 Array Biopharma Inc. Kristalinske oblike 1-(3-tert-butil-1-P-tolil-1H-pirazol-5-il)-3- (5-fluoro-2-(1-(2-hidroksietil)-1H-indazol-5-iloksi)benzil)urea hidroklorida
WO2014134313A1 (en) 2013-02-27 2014-09-04 Array Biopharma Inc. Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019114792A1 (zh) * 2017-12-13 2019-06-20 劲方医药科技(上海)有限公司 一种TGF-βRI抑制剂的晶型、盐型及其制备方法
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
CN115850179B (zh) * 2022-12-13 2025-03-25 北京科翔中升医药科技有限公司 一种氘代吲唑类mapk抑制剂药物及用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
JPS5998060A (ja) 1982-11-27 1984-06-06 Fujisawa Pharmaceut Co Ltd インダゾ−ル誘導体、その製造法および農薬
US4571255A (en) * 1983-12-29 1986-02-18 Ppg Industries, Inc. Subsituted phenoxybenzisoxazole herbicides
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
US5234942A (en) * 1984-10-19 1993-08-10 Ici Americas Inc. Heterocyclic amides and leucotriene antagonistic use thereof
SU1545940A3 (ru) 1984-10-19 1990-02-23 Ай-Си-Ай Америказ Инк (Фирма) Способ получени гетероциклических кислот или их солей
PL265549A1 (en) 1985-03-26 1988-09-01 The method of manufacture of new heterocyclic amides
JPS6368568A (ja) 1986-09-10 1988-03-28 Otsuka Pharmaceut Factory Inc ｐ−アミノフエノ−ル誘導体
NZ224714A (en) 1987-06-01 1990-03-27 Janssen Pharmaceutica Nv Substituted benzotriazole derivatives and pharmaceutical compositions
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
BR9305569A (pt) * 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
AU682947B2 (en) 1994-05-27 1997-10-23 Mochida Pharmaceutical Co., Ltd. Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
KR19990064117A (ko) 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EA002113B1 (ru) 1996-09-04 2001-12-24 Пфайзер Инк. Производные индазола и их использование в качестве ингибиторов фосфодиэстеразы (фдэ) типа iv и продуцирования фактора некроза опухоли (фно)
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
EA199900452A1 (ru) 1996-11-08 2000-02-28 Дюпон Фармасьютикалз Компани 1-(3-аминоиндазол-5-ил)-3-фенилметилциклические мочевины, полезные в качестве ингибиторов вич-протеазы
US6218386B1 (en) * 1996-11-08 2001-04-17 Dupont Pharmaceuticals A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5965583A (en) * 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1019394A1 (en) * 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9812944A (pt) * 1997-10-20 2000-08-08 Hoffmann La Roche Inibidores bicìclicos da cinase
EP1028953A1 (en) * 1997-11-03 2000-08-23 Boehringer Ingelheim Pharmaceuticals Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
IL135900A0 (en) 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
US6329412B1 (en) * 1997-11-04 2001-12-11 Pfizer Inc Bisamidine compounds as antiproliferative agents
IL135714A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
GB9820767D0 (en) 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
CA2360934A1 (en) * 1999-02-22 2000-08-31 Lin-Hua Zhang Polycyclo heterocyclic derivatives as antiinflammatory agents
JP2002539206A (ja) * 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
ATE278674T1 (de) * 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
WO2000057861A2 (en) * 1999-03-29 2000-10-05 Shire Biochem Inc. Use of cytidine derivatives for the treatment of leukaemia
AU4063600A (en) 1999-04-05 2000-10-23 Merck & Co., Inc. A method of treating cancer
US6355636B1 (en) * 1999-04-21 2002-03-12 American Cyanamid Company Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases
ES2216884T3 (es) 1999-04-21 2004-11-01 Wyeth Holdings Corporation 3-ciano-(1.7),(1.5) y (1.8)-naftiridina sustituidas que son inhibidores de tirosina-quinasas.
JP2003500403A (ja) 1999-05-21 2003-01-07 サイオス，インコーポレーテッド ｐ３８キナーゼのインヒビターとしてのインドール型誘導体
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CA2374737C (en) * 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
AU1899501A (en) 1999-11-27 2001-06-04 Dong Wha Pharmaceutical Industrial Co., Ltd. Novel 3-nitropyridine derivatives and the pharmaceutical compositions containingsaid derivatives
CN1610667A (zh) * 1999-11-27 2005-04-27 同和药品工业株式会社 新型3－硝基吡啶衍生物和含有该衍生物的药物组合物
AU4890301A (en) * 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
EP1341782A2 (en) * 2000-11-20 2003-09-10 Scios Inc. Inhibitors of p38 kinase
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
HUP0303415A2 (hu) * 2001-03-09 2004-01-28 Pfizer Products Inc. Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
BR0212841A (pt) * 2001-09-26 2004-08-03 Pharmacia Italia Spa Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
EP1438048A1 (en) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
WO2003051847A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
EP1480973B1 (en) * 2002-02-25 2008-02-13 Boehringer Ingelheim Pharmaceuticals Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2003087072A1 (en) 2002-03-29 2003-10-23 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for endothelial disorder
DE60325984D1 (de) 2002-07-19 2009-03-12 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
JP4648703B2 (ja) 2002-09-05 2011-03-09 アベンティス・ファーマ・ソシエテ・アノニム 医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
KR20050071598A (ko) * 2002-10-24 2005-07-07 메르크 파텐트 게엠베하 라프-키나아제 억제제로서의 메틸렌 우레아 유도체
ES2273047T3 (es) * 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
GB0320244D0 (en) 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
US7129252B2 (en) 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005063715A1 (en) 2003-12-18 2005-07-14 Boehringer Ingelheim Pharmaceuticals, Inc. Polymorph of birb 796, a p38map kinase inhibitor
CN1894240A (zh) 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
WO2006122230A1 (en) * 2005-05-11 2006-11-16 Array Biopharma Inc. P38 inhibitors and methods of use thereof
RS52298B (sr) 2006-01-31 2012-12-31 Array Biopharma Inc. Inhibitori kinaze i postupak njihove upotrebe

Also Published As

Publication number Publication date
RU2442777C2 (ru) 2012-02-20
IL192949A0 (en) 2009-02-11
RS52298B (sr) 2012-12-31
WO2007089646A1 (en) 2007-08-09
IL219644A0 (en) 2012-06-28
UA94733C2 (ru) 2011-06-10
AU2007210073A1 (en) 2007-08-09
TW200808774A (en) 2008-02-16
IL219643A0 (en) 2012-06-28
EP1981851B1 (en) 2012-01-25
BRPI0707401B8 (pt) 2022-12-20
TWI388557B (zh) 2013-03-11
PL1981851T3 (pl) 2012-07-31
CA2635813A1 (en) 2007-08-09
KR20090003194A (ko) 2009-01-09
IL219643A (en) 2013-11-28
JP2009525330A (ja) 2009-07-09
RU2008135332A (ru) 2010-03-10
ES2379656T3 (es) 2012-04-30
BRPI0707401A2 (pt) 2011-05-03
CY1112770T1 (el) 2016-02-10
HK1123548A1 (en) 2009-06-19
BRPI0707401B1 (pt) 2020-09-15
AU2007210073B2 (en) 2011-10-06
KR101357465B1 (ko) 2014-02-03
MY151835A (en) 2014-07-14
DK1981851T3 (da) 2012-03-19
IL219644A (en) 2014-08-31
ATE542800T1 (de) 2012-02-15
EP1981851A1 (en) 2008-10-22
IL192949A (en) 2012-12-31
JP5131990B2 (ja) 2013-01-30
NZ570846A (en) 2011-08-26
ZA200806507B (en) 2009-10-28
SI1981851T1 (sl) 2012-05-31
PT1981851E (pt) 2012-04-13
SG175599A1 (en) 2011-11-28
US20110124878A1 (en) 2011-05-26
HRP20120256T1 (hr) 2012-04-30
US20090023795A1 (en) 2009-01-22
CA2635813C (en) 2014-01-07
US8039639B2 (en) 2011-10-18
CN101415685A (zh) 2009-04-22
US8044083B2 (en) 2011-10-25

Similar Documents

Publication Publication Date Title
CN101415685B (zh) 激酶抑制剂及其使用方法
ES3023366T3 (en) Heteroalkyl dihydroquinoline sulfonamide compounds
ES2637721T3 (es) Macrociclos como inhibidores de quinasa
JP7106572B2 (ja) 免疫調節剤として有用な化合物
US10287252B2 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
US10167257B2 (en) Indole derivatives for use in medicine
ES2777123T3 (es) Pirazol para el tratamiento de trastornos autoinmunes
EP3191484B1 (en) Pyrazolopyridine derivatives and their use in therapy
ES2682043T3 (es) Ibrutinib deuterado
JP7595355B2 (ja) 化合物
WO2021068898A1 (zh) 新颖的kras g12c蛋白抑制剂及其制备方法和用途
TW201102369A (en) Quinazoline derivatives
CA2965741A1 (en) Pharmaceutical compound
CA2918910A1 (en) Inhibitors of transcription factors and uses thereof
BR122014012788A2 (pt) derivados de pirimidina fundidos, seus usos, e composição farmacêutica para inibição da atividade de tirosina quinase
JP7455133B2 (ja) インドールアミン－２，３－ジオキシゲナーゼ阻害活性を有するキノロン誘導体
GB2508652A (en) Heterocyclic piperazine derivatives
EP3774767A1 (en) Aryl hydrocarbon receptor modulators and uses thereof
BR112019022553A2 (pt) novo derivado de tetrahidronaftil ureia
TW202317563A (zh) 一種聯苯類衍生物抑制劑的晶型及其製備方法
CN115417867A (zh) 取代萘甲酰胺类衍生物及其医药用途
CN107531685A (zh) 具有抗肿瘤活性的化合物
KR102636651B1 (ko) 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도
JP7247106B2 (ja) 内臓痛の治療のための化合物および方法
CA2943001A1 (en) Inhibitors of the wnt signalling pathways

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant